CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 By Investing.com
Preliminary results from phase 1 of CT071 (NCT05838131) were presented as a poster at the 29th Annual Environmental Health Association (EHA) Conference on
“Multiple myeloma is a common but incurable hematological malignancy with significant unmet need. Despite numerous recent advances, most patients relapse and become resistant to available treatments, and thus new treatments are needed.” GPRC5D, a protein that is expressed in Significant on the surface of malignant plasma Cells with limited expression on normal tissues represent a promising target for the treatment of multiple myeloma CT071 is an autologous second-generation CAR T cell product that targets GPRC5D and was manufactured using accelerator CARcelerate.™ The platform shortens manufacturing time to approximately 30 hours, supporting shorter vein-to-vein time and younger T cells. “Preliminary results of the ongoing study presented at EHA show that CT071 has the potential to be a best-in-class GPRC5D targeting CAR-T therapy.”
From
Median follow-up at the time of data cutoff was 4.07 months (range: 2.8-7.4). There were no grade 3 or higher cytokine release syndrome (CRS) events. No immune cell-associated neurotoxicity syndrome (ICANS) was observed. No adverse events of particular interest or dose-limiting toxicities (DLT) occurred. Four patients experienced treatment-related SAEs, including pneumonia (n = 1), decreased appetite (n = 1) and thrombocytopenia (n = 2), and all of them recovered.
The overall response rate was 90%, including 5 patients (50%) with a strict complete response (sCR), 2 patients (20%) with a very good partial response (VGPR), and 2 patients (20%) with a partial response (PR). . All nine patients who had an evaluable MRD at week 4 achieved MRD negativity (10-6 threshold) ), including all five patients with sCR/CR. Pharmacokinetic analysis showed robust cell expansion and viability, with a mean Tthe above 14 days (range: 12-28) and median Cthe above of 32280.5 copies/g gDNA (range: 8372-106060).
About CT071
CT071 is a CAR T cell therapy candidate developed with CARsgen's proprietary CARcelerate.™ A platform targeting GPRC5D for the treatment of R/R MM or relapsed/refractory plasma cell leukemia (“R/R PCL”). The investigator-initiated trial (NCT05838131) is ongoing
on CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company operating in
Forward-looking statements
All statements in this press release that do not represent historical fact or that do not relate to current facts or current circumstances are forward-looking statements. These forward-looking statements express the Group's current views, expectations, beliefs and expectations with respect to future events as of the date of this press release. These forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release may not occur. These risks and uncertainties include, but are not limited to, those detailed under “Principal Risks and Uncertainties” in our most recent Annual Report and Interim Report and other announcements and reports available on our corporate website, https://www. carsgen.com. No representation or warranty is made as to completion or reasonableness, and no reliance should be placed on any expectations, targets, estimates or forecasts contained in this press release.
reference
(1) Jie Du, et al. EHA 2024. June 2024; Poster p. 941